Targeted Therapies in Development for Melanoma

February 19, 2014
Georgina Long, BSc, PhD, MBBS, FRACP

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.

Clinical Pearls

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.

  • Trials are planned looking at several targeted therapies and combinations of therapies, including CDK 4/6 inhibitors, BRAF or MEK inhibitors combined with MDM2 inhibitors, and BRAF plus MEK inhibitors combined with PD-1 antibodies
  • Inhibition at the top of a pathway may not be the most efficacious strategy, as in the case of receptor tyrosine kinase inhibitors
  • Long favors approaching treatment with the immune system or with inhibitors of AKT/PI3K, CDK 4/6, or HDAC